About FDA

NCTR Research Highlights

 Red envelope icon for GovdeliveryGet e-mail updates when this information changes.

Current Highlight from December 2, 2016

Intrinsic Resistance of Burkholderia cepacia Complex to Antiseptics      

Scientists from FDA's NCTR and Center for Drug Evaluation and Research, and the University of Michigan have shown that resistance of Burkholderia cepacia complex (BCC) bacteria to benzalkonium chloride (BZK) is due to intrinsic resistance mechanisms which include removal of BZK by efflux pumps and the metabolic inactivation of BZK by catabolic enzymes. The study evaluated the susceptibility of 20 BCC strains to BZK and used metabolic and proteomic approaches to determine the mechanisms responsible for the antiseptic resistance of BCC, which was not well understood until now. BZK is a commonly used antiseptic in pharmaceutical formulations in the United States, and a number of microbial outbreaks have been linked to antiseptics contaminated with BCC bacteria, which are opportunistic pathogens. The article is available online at mBiodisclaimer icon.

For more information, please contact Carl Cerniglia, Division Director, Division of Microbiology, FDA/NCTR.  

Contact FDA

National Center for Toxicological Research

Food and Drug Administration

3900 NCTR Road

Jefferson, AR 72079

Page Last Updated: 12/08/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English